大洋生物拟用不超3亿元闲置自有资金进行现金管理

Core Viewpoint - Zhejiang Dayang Biotechnology Group Co., Ltd. announced the use of idle self-owned funds for cash management, approving up to 300 million yuan for investment in low-risk financial products [1][3]. Cash Management Overview - The company will use no more than 300 million yuan of idle self-owned funds for cash management, with a focus on high safety, good liquidity, and controllable risk financial products [1]. - The investment period is valid for 12 months from the date of board approval, and the funds can be rolled over within this period [1]. - The funds are sourced from temporarily idle self-owned funds, ensuring that daily operations are not affected [1]. Investment Risk and Control Measures - Although the purchased financial products are low-risk, the company acknowledges potential market volatility impacts [2]. - Funds within the approved limit can only be used for low-risk financial products with a maturity of no more than 12 months [2]. - The finance department will monitor account transactions and balances, while the audit department will conduct quarterly checks on investment projects [2]. Impact on Company Operations - The use of idle funds for financial products will not affect the company's normal operations and is expected to enhance fund utilization efficiency and generate investment returns for shareholders [3]. - The board and supervisory committee have approved the cash management plan, confirming that it will not harm the interests of the company or its shareholders [3].